Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The treatment of acute and chronic severe pain remains a common major challenge faced by clinicians working with the
general population, and even after recent advances in the treatment of acute and chronic severe pain, there can continue to
be manifestations of adverse effects. Chronic pain affects the personal and social life of the patient, and often also their families.
In some cases, after an acute pain the patient continues to experience chronic pain, which can be a result of diseases such
as cancer. There is growing evidence that omega-3 fatty acids can contribute to the reduction of pain. This presentation will
describe an innovative technological development, both in its pharmaceutical composition (either morphine or methadone
with omega-3 fatty acids) and in the pharmacological treatments associated with its use. In addition, the preclinical evidence
concerning the analgesic effects of omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) will also be explored.
The main advantage of new pharmacological treatments using these pharmaceutical compositions lies in an improved pain
control with a sub-therapeutic dose of these opioids, which can lead to the elimination or at least potential reduction of adverse
effects.